Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SPTX
SPTX logo

SPTX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
18.000
Open
18.000
VWAP
--
Vol
--
Mkt Cap
--
Low
18.000
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Events Timeline

(ET)
2026-05-01
07:30:00
Goldman Sachs and Others Increase Stock Offering Size to 14.2M Shares
select

News

seekingalpha
8.5
15:11 PMseekingalpha
Hemab and Seaport Price IPOs to Raise Over $550M
  • Hemab IPO Details: Hemab Therapeutics priced its IPO at $18.00 per share for 16.75 million shares, raising approximately $301.5 million, indicating strong market demand for its bleeding disorder treatments and solidifying its position in the biotech sector.
  • Seaport IPO Pricing: Seaport Therapeutics priced nearly 14.2 million shares at $18.00 each, expecting to raise about $254.9 million, reflecting investor confidence in its neuropsychiatric drug development and providing crucial funding support in a competitive biopharmaceutical market.
  • Underwriter Options: Both companies have granted underwriters a 30-day option, with Hemab allowing for an additional 2.5 million shares and Seaport 2.1 million shares, a strategy that not only provides additional funding flexibility but could also enhance fundraising if market demand remains strong.
  • Market Response and Timeline: Both firms aim to close their offerings on May 4, and the positive market response to these IPOs may drive overall investment enthusiasm in the biotech sector, attracting more investor attention to emerging biopharmaceutical companies.
renaissancecapital
8.5
14:09 PMrenaissancecapital
April IPO Market Rebounds with $7.3 Billion Raised
  • Significant Fundraising Surge: In April, 13 IPOs raised a total of $7.3 billion, with the latter half of the month seeing larger deals that pushed proceeds well above the historical average of $3.3 billion despite early volatility in March.
  • Large Deals Leading the Market: Twelve IPOs raised over $100 million, notably Madison Air (MAIR) completing the largest offering of the year, indicating strong demand for sizable projects in the current market.
  • Strong Investment Returns: Traditional IPOs averaged a robust 34% return by month-end, with nearly all trading above their issue price, reflecting a gradual restoration of market confidence in new listings.
  • Increased Market Activity: With IPO filings reaching a year-to-date high, improved market conditions and solid returns are encouraging more companies to prepare for listings, suggesting an acceleration of IPO activity in the coming weeks.
renaissancecapital
8.5
13:08 PMrenaissancecapital
Seaport Therapeutics Raises $255 Million in IPO for Neuropsychiatric Therapies
  • Oversubscribed Financing: Seaport Therapeutics successfully raised $255 million by offering 14.2 million shares at $18 each, exceeding initial plans by over 10%, reflecting strong market confidence in its neuropsychiatric treatment solutions.
  • Significant Shareholder Participation: Existing shareholder General Atlantic indicated $50 million worth of shares in the offering, representing 20% of the deal, which not only bolsters investor trust in the company but also provides essential funding for future growth.
  • Technological Platform Advantage: Seaport leverages its proprietary Glyph platform, focusing on improving oral bioavailability and reducing first-pass metabolism, aiming to reformulate clinically validated mechanisms into differentiated product candidates, showcasing its innovative capabilities in biotechnology.
  • Clear Clinical Progress: The company's lead programs include GlyphAllo in Phase 2b for major depressive disorder and GlyphAgo in Phase 1 for generalized anxiety disorder, with these advancements laying a solid foundation for its future market performance.
Wall Street analysts forecast SPTX stock price to rise
0 Analyst Rating
Wall Street analysts forecast SPTX stock price to rise
0 Buy
0 Hold
0 Sell
Current: 0.000
sliders
Low
Averages
High
Current: 0.000
sliders
Low
Averages
High
No data

No data

Valuation Metrics

The current forward P/E ratio for Seaport Therapeutics, Inc. (SPTX.O) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Seaport Therapeutics, Inc.'s fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
Current PE
NaN
Overvalued PE
Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
Current EV/EBITDA
NaN
Overvalued EV/EBITDA
Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
Current PS
NaN
Overvalued PS
Undervalued PS

Financials

AI Analysis
Annual
Quarterly

Whales Holding SPTX

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Seaport Therapeutics, Inc. (SPTX) stock price today?

The current price of SPTX is 18 USD — it has increased 0

What is Seaport Therapeutics, Inc. (SPTX)'s business?

What is the price predicton of SPTX Stock?

Wall Street analysts forecast SPTX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SPTX is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Seaport Therapeutics, Inc. (SPTX)'s revenue for the last quarter?

Seaport Therapeutics, Inc. revenue for the last quarter amounts to NaN USD, decreased

What is Seaport Therapeutics, Inc. (SPTX)'s earnings per share (EPS) for the last quarter?

Seaport Therapeutics, Inc.. EPS for the last quarter amounts to USD, decreased

How many employees does Seaport Therapeutics, Inc. (SPTX). have?

Seaport Therapeutics, Inc. (SPTX) has 0 emplpoyees as of May 01 2026.

What is Seaport Therapeutics, Inc. (SPTX) market cap?

Today SPTX has the market capitalization of 0.00 USD.